Top-Rated StocksTop-RatedNASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis → Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad) Free CRNX Stock Alerts $44.27 +0.83 (+1.91%) (As of 12:50 PM ET) Add Compare Share Share Today's Range$42.05▼$44.7850-Day Range$35.99▼$48.0352-Week Range$15.76▼$49.58Volume162,739 shsAverage Volume769,566 shsMarket Capitalization$3.08 billionP/E RatioN/ADividend YieldN/APrice Target$54.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Crinetics Pharmaceuticals alerts: Email Address Crinetics Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside22.3% Upside$54.17 Price TargetShort InterestBearish7.05% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment0.60Based on 5 Articles This WeekInsider TradingSelling Shares$8.62 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.34) to ($3.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.81 out of 5 starsMedical Sector241st out of 910 stocksPharmaceutical Preparations Industry96th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCrinetics Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.05% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently decreased by 2.00%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCrinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Crinetics Pharmaceuticals is -0.62. Previous Next 3.1 News and Social Media Coverage News SentimentCrinetics Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Crinetics Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest12 people have searched for CRNX on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,621,177.00 in company stock.Percentage Held by InsidersOnly 7.00% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.34) to ($3.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -11.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More CRNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRNX Stock News HeadlinesApril 18, 2024 | insidertrades.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 14,375 Shares of StockApril 9, 2024 | insidertrades.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) CEO Sells $2,013,560.67 in StockApril 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 3, 2024 | insidertrades.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Stephanie Okey Sells 17,500 SharesMarch 27, 2024 | insidertrades.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) COO Sells 32,359 Shares of StockMarch 23, 2024 | insidertrades.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Dana Pizzuti Sells 15,089 SharesApril 19, 2024 | americanbankingnews.comDana Pizzuti Sells 14,375 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) StockApril 14, 2024 | americanbankingnews.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 7.8%April 23, 2024 | Crypto 101 Media (Ad)Incredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.April 12, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 28, 2024 | investing.comCrinetics Pharmaceuticals COO sells shares worth over $1.4 millionMarch 28, 2024 | insidermonkey.comInsiders Are Dumping These 5 Healthcare StocksMarch 27, 2024 | finance.yahoo.comInsider Sell: COO Jeff Knight Sells 32,359 Shares of Crinetics Pharmaceuticals Inc (CRNX)March 22, 2024 | finance.yahoo.comDirector Matthew Fust Sells 60,000 Shares of Crinetics Pharmaceuticals Inc (CRNX)March 22, 2024 | finance.yahoo.comInsider Sell: Chief Medical and Development Officer Dana Pizzuti Sells 15,089 Shares of ...March 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals on Paltusotine’s Clinical Success and Market PotentialMarch 21, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals Amid Impressive Paltusotine Trial ResultsMarch 21, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Inc CFO Marc Wilson Sells 6,942 SharesMarch 19, 2024 | marketwatch.comCrinetics Pharmaceuticals Up on Positive Results for Acromegaly Drug TrialMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)March 19, 2024 | benzinga.comEndocrine Disease-Focused Crinetics Pharmaceuticals Stock Soars On Tuesday - Here's WhyMarch 19, 2024 | finance.yahoo.comCrinetics Stock Jets 16% Higher, Reversing A Three-Week Decline On Its Phase 3 WinMarch 19, 2024 | markets.businessinsider.comCrinetics Pharma Reports Positive Results From Phase 3 Studies Of Paltusotine For AcromegalyMarch 19, 2024 | reuters.comCrinetics Pharma's hormonal disorder drug meets main goal in late-stage studyMarch 19, 2024 | msn.comCrinetics gains as late-stage trial for lead drug succeedsSee More Headlines Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CRNX CUSIPN/A CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Stock Price Target$54.17 High Stock Price Target$80.00 Low Stock Price Target$35.00 Potential Upside/Downside+24.7%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-214,530,000.00 Net Margins-4,223.27% Pretax Margin-5,216.32% Return on Equity-52.93% Return on Assets-45.54% Debt Debt-to-Equity RatioN/A Current Ratio13.07 Quick Ratio13.07 Sales & Book Value Annual Sales$4.01 million Price / Sales753.97 Cash FlowN/A Price / Cash FlowN/A Book Value$8.07 per share Price / Book5.38Miscellaneous Outstanding Shares69,600,000Free Float64,728,000Market Cap$3.02 billion OptionableOptionable Beta0.63 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. R. Scott Struthers Ph.D. (Age 62)Founder, President, CEO & Director Comp: $870.69kDr. Stephen F. Betz Ph.D. (Age 58)Founder & Chief Scientific Officer Comp: $618.58kMr. Marc J. C. Wilson (Age 45)Chief Financial Officer Comp: $585.54kMr. James Hassard (Age 58)Chief Commercial Officer Comp: $513.34kDr. Dana Pizzuti M.D. (Age 68)Chief Development Officer Comp: $493.62kMr. Jeff E. Knight (Age 53)Chief Operating Officer Comp: $237.64kMs. Garlan AdamsGeneral Counsel & Corporate SecretaryMs. Adriana Cabre M.B.A.Chief Human Resources OfficerDr. Alan S. Krasner M.D. (Age 61)Chief Medical Officer Comp: $571.97kMr. Kevin CappsHead of Intellectual PropertyMore ExecutivesKey CompetitorsRayzeBioNASDAQ:RYZBAvadel PharmaceuticalsNASDAQ:AVDLAkero TherapeuticsNASDAQ:AKROIcosavaxNASDAQ:ICVXBicycle TherapeuticsNASDAQ:BCYCView All CompetitorsInsiders & InstitutionsHennion & Walsh Asset Management Inc.Bought 927 shares on 4/17/2024Ownership: 0.055%Dana PizzutiSold 14,375 sharesTotal: $639,256.25 ($44.47/share)Richard Scott StruthersSold 40,951 sharesTotal: $2.01 M ($49.17/share)Stephanie OkeySold 17,500 sharesTotal: $811,650.00 ($46.38/share)Nomura Holdings Inc.Sold 35,000 shares on 3/27/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CRNX Stock Analysis - Frequently Asked Questions Should I buy or sell Crinetics Pharmaceuticals stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRNX shares. View CRNX analyst ratings or view top-rated stocks. What is Crinetics Pharmaceuticals' stock price target for 2024? 12 Wall Street analysts have issued twelve-month target prices for Crinetics Pharmaceuticals' stock. Their CRNX share price targets range from $35.00 to $80.00. On average, they expect the company's stock price to reach $54.17 in the next year. This suggests a possible upside of 22.3% from the stock's current price. View analysts price targets for CRNX or view top-rated stocks among Wall Street analysts. How have CRNX shares performed in 2024? Crinetics Pharmaceuticals' stock was trading at $35.58 at the start of the year. Since then, CRNX stock has increased by 24.5% and is now trading at $44.28. View the best growth stocks for 2024 here. When is Crinetics Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CRNX earnings forecast. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative trailing twelve-month return on equity of 52.93% and a negative net margin of 4,223.27%. The business's revenue was down 100.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.84) EPS. What ETFs hold Crinetics Pharmaceuticals' stock? ETFs with the largest weight of Crinetics Pharmaceuticals (NASDAQ:CRNX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), BNY Mellon Innovators ETF (BKIV), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and First Trust BuyWrite Income ETF (FTHI). What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO? 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC). When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Crinetics Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers, Stephanie Okey and Stephen F Betz. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CRNX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
